Overview
JUNS market data
Price History
JUNS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.01 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -11,463.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.61 – $138.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.1M · P/B 84.90 · P/S 101.09.
Company News
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Aug 7, 2026, 12:55 PM
8-K filing — JUPITER NEUROSCIENCES, INC. (JUNS)SEC EDGAR · Aug 6, 2026, 12:56 PM
Jupiter Neurosciences shares are trading lower after the company announced a 1-for-75 reverse stock split.Benzinga · Aug 5, 2026, 12:48 PM
Jupiter Neurosciences Announces 1-For-75 Reverse Stock Split, Effective Aug. 6Benzinga · Aug 5, 2026, 12:03 PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Jul 24, 2026, 5:05 PM
12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · Jul 23, 2026, 5:05 PM
Jupiter Neurosciences shares are trading higher after the company announced it signed a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002.Benzinga · Jul 21, 2026, 3:17 PM
Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone PaymentsBenzinga · Jul 21, 2026, 11:16 AM
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving PremarketBenzinga · Jun 29, 2026, 11:05 AM
Jupiter Neurosciences Registers Resale Of Up To 16M Shares By Selling StockholdersBenzinga · Jun 26, 2026, 8:40 PM